Hello, Fool! | Login | Signup | My Fool
Oct 15, 2008 7:33 PM ET | Feedback | Site Changes | Help
The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.
View All Commentary (HGSI)
Recs
TMFBreakerBrian (99.83) Submitted: 5/16/08 6:28 AM : Start Price: $6.03 HGSI Score: 7.33
Good science. Multiple revenue sources. Bad lead drugs (compared to the competition)
Report this Post Replies: 0 | Reply
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK